06.11.15
Paratek Pharmaceuticals, Inc., a biopharma company focused on the development of therapies based on tetracycline chemistry, has opened a new office near Philadelphia in King of Prussia, PA.
Paratek, headquartered in Boston, currently employs 11 people in the Philadelphia area and expects to add more in the next year as it advances its lead clinical product candidate, omadacycline, a new once-daily oral and intravenous, broad-spectrum antibiotic for use as empiric monotherapy for serious community-acquired bacterial infections.
"With two important antibiotic products in development, we have been growing our team rapidly. Our presence in Philadelphia enables us to attract world-class talent from the area's biopharmaceutical industry," said Evan Loh, president and chief medical officer, Paratek. "This has already helped us identify and recruit key talent and will be critical as we continue to grow going forward."
Paratek, headquartered in Boston, currently employs 11 people in the Philadelphia area and expects to add more in the next year as it advances its lead clinical product candidate, omadacycline, a new once-daily oral and intravenous, broad-spectrum antibiotic for use as empiric monotherapy for serious community-acquired bacterial infections.
"With two important antibiotic products in development, we have been growing our team rapidly. Our presence in Philadelphia enables us to attract world-class talent from the area's biopharmaceutical industry," said Evan Loh, president and chief medical officer, Paratek. "This has already helped us identify and recruit key talent and will be critical as we continue to grow going forward."